The government is taking steps to curb use of some long-acting asthma drugs taken by millions, issuing safety restrictions Thursday to lower an uncommon but potentially life-threatening risk that ...
Government health advisers Thursday called for restrictions on some long-acting asthma drugs, but spared Advair, a top-selling medication used by millions of patients. Government health advisers ...
HERTFORDSHIRE, England, and PITTSBURGH, May 18, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced four scientific abstracts from the Wixela™ Inhub™ ...
NEW YORK — The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration on Wednesday approved Mylan’s version in three ...
Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline's GSK Advair Diskus - Wixela Inhub - following a few setbacks. Notably, this is the first ...
If Mylan’s aggressive pricing for its generic Advair product sounds familiar, that’s because it is. The knockoffs giant set the list price for Wixela Inhub, its copy of GlaxoSmithKline’s respiratory ...
GlaxoSmithKline’s respiratory blockbuster Advair may have once been a top target for generics, but now Novartis is backing out of its copycat program—and paying a hefty price. It's not just a blow to ...
wixela-product-image Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), the first substitutable generic of Advair Diskus (GlaxoSmithKline), has been made available by Mylan Mylan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results